Target discovery opportunities using machine learning on longitudinal patient journeys.

Presenter: Ramneek Gupta-Head of Computational Biology

For almost 100 years, Novo Nordisk have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, eg insulin pens. Their treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From their labs they are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.